MetaCap

MacroGenics (MGNX) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MacroGenics (MGNX) has outperformed OnKure Therapeutics (OKUR) over the past year, gaining 40.0% versus a gain of 4.7%. Over five years, MGNX leads with a -89.6% price change compared with -96.2% for OKUR. MacroGenics is the larger company by market cap ($125.3 million vs $111.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MGNX+40.00%OKUR+4.65%
+260%+114%-32%
Nov 21, 20251 yearNov 20, 2026
MGNX-89.43%OKUR-96.62%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MGNX versus OKUR key metrics
MetricMGNXOKUR
Share price$1.96$2.70
Market cap$125.26M$111.21M
1-day change-1.01%-2.17%
YTD return+21.74%-6.90%
1-year return+40.00%+4.65%
5-year return-89.56%-96.16%
EPS (TTM)$-2.30$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$149.50M—
Revenue growth (YoY)-0.31%—
Net income (latest FY)$-74.62M$-59.52M
Gross margin100.00%—
Operating margin-48.72%—
Net margin-49.91%—
52-week high$5.08$5.38
52-week low$1.32$2.01
Distance from 52-week high-61.42%-49.81%
Analyst consensusbuynone
Avg. price target upside+308.16%+464.81%
Average volume747.02K335.78K
Shares outstanding63.91M40.50M
Employees29345
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGNX has outperformed OKUR by 35.3 percentage points over the past year.

About MacroGenics

MGNX stock →

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

MGNX vs OKUR FAQ

Which is bigger, MacroGenics or OnKure Therapeutics?

MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $111.21M for OnKure Therapeutics (OKUR).

Which stock has performed better over the past year, MGNX or OKUR?

MGNX returned +40.00% over the past 12 months, compared with +4.65% for OKUR (price return, excluding dividends). Past performance does not predict future results.

Are MacroGenics and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons